Jubilant Pharmova Q4 Results
- BSE: 530019
- NSE: JUBLPHARMA
- ISIN: INE700A01033
- Sector: Biotechnology & Drugs
BSE
817.45
-19.70 (-2.35%)
-19.70 (-2.35%)Volume6.33 K
Updated: Fri 6 Mar, 2026 | 15:52:03
NSE
819.05-17.50 (-2.09%)
-17.50 (-2.09%)Volume1.54 L
Updated: Fri 6 Mar, 2026 | 15:25:53
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q4 Results Highlights
Quarter ended Mar 25
Note: Comparison is on QoQ basis
Quarterly - Jubilant Pharmova Q4 Results
*All figures in crores except per share values
| Fiscal Period | Mar 25 | Dec 25 | QoQ Comp | Mar 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 1,681.90 | 1,993.40 | 2.27% | 1,757.10 | -4.28% |
| Depreciation/ Amortization | 95.20 | 120.70 | 4.27% | 101.00 | -5.74% |
| Operating Income | 246.90 | 129.10 | 39.33% | 1.50 | 16360.00% |
| Net Income | 153.60 | 55.90 | 52.23% | -58.60 | 0.00% |
| Other Operating Expenses Total | 366.70 | 410.30 | -8.28% | 404.80 | -9.41% |
| Net Income Before Taxes | 206.00 | 93.40 | 57.85% | -53.70 | 0.00% |
| Total Revenue | 1,928.80 | 2,122.50 | 5.88% | 1,758.60 | 9.68% |
| Selling/ General/ Admin Expenses Total | 590.60 | 706.40 | 5.45% | 555.00 | 6.41% |
| Diluted Normalized EPS | 9.82 | 5.01 | 34.89% | 3.25 | 202.49% |